News
09-01-2023, 07:43 AM
Amgen today announced the*U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee*(ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS®*(sotorasib) for adults with previously treated locally advanced or metastatic*KRAS*G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on*Oct. 5, 2023.
More... (https://www.news-medical.net/news/20230901/Amgen-to-discuss-application-for-LUMAKRASc2ae-(sotorasib)-for-the-treatment-of-KRAS-g12c-positive-NSCLC-at-FDA-advisory-committee-meeting.aspx)
More... (https://www.news-medical.net/news/20230901/Amgen-to-discuss-application-for-LUMAKRASc2ae-(sotorasib)-for-the-treatment-of-KRAS-g12c-positive-NSCLC-at-FDA-advisory-committee-meeting.aspx)